SmartKem rakes in Series A funds

SmartKem has secured “significant” Series A funding. The investors were BASF Venture Capital, Octopus Investments, Entrepreneurs Fund and Finance Wales. Based in the UK, SmartKem is a provider of semiconductor materials.


OptiNose grabs Series C-1 funds

OptiNose said Monday that it has received an undisclosed amount of Series C-1 funding. The company’s investors include Avista Capital Partners, WFD Ventures and Entrepreneurs Fund. Headquartered in Yardley, Penn., OptiNose is a specialty pharmaceutical firm that’s built around a nasal delivery platform.

Sequana Medical raises Series C

Sequana Medical has raised CHF 23 million ($26.2 million) in a Series C preferred share financing round led by Life Science Partners and co-led by NeoMed Management, VI Partners, BioMedInvest, Entrepreneurs Fund and Capricorn Venture Partners. The business is a Swiss medical device company.

CYTOO and Cenix Join Forces

Grenoble, France-based CYTOO, a a provider of innovative enabling technologies for high content cell analysis, has teamed up with Cenix BioScience, a developer of industrial high-content screening applications of RNAi. CYTOO in November closed of a series C funding round of $10 million. New investors, Sham and Entrepreneurs Fund (EF), led the round. Existing investors […]

General Fusion Rounds up Nearly $20M in Series B

General Fusion is having a happy Cinco de Mayo. The utility-scale fusion power company reeled in $19.5 million in a Series B round that included investors Cenovus Energy, through its Environmental Opportunity Fund, Bezos Expeditions, the personal investment company of Jeff Bezos, Chrysalix Energy Venture Capital, GrowthWorks, Braemar Energy Ventures, Entrepreneurs Fund, Business Development Bank of Canada (BDC), and SET Venture Partners.

NovaShunt Raises $25M in Series B

Swiss medical device start-up NovaShunt AG has raised roughly $25 million in Series B financing. BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund co-led the round, which included participation from existing shareholders NeoMed and VI Partners. NovaShunt is developing an implantable pump system that continually removes excess abdominal fluid in patients suffering from liver cirrhosis, certain cancers and congestive heart failure.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget